Implants News and Research

RSS

Abbott reports positive 6-month results from bioresorbable vascular scaffold trial at EuroPCR 2010

Abbott today announced positive six-month results from the first 45 patients enrolled in the second stage of the ABSORB trial, which was presented during the Late-Breaking Clinical Trials session at the EuroPCR 2010 conference. At six months, Abbott's bioresorbable vascular scaffold (BVS) demonstrated strong results, with a low (4.4 percent) rate of major adverse cardiac events (MACE) and no blood clots (thromboses).

26 May 2010

6-month results of NovoStent's SAMBA trial for atherosclerotic disease in SFA and popliteal arteries

NovoStent Corporation, a privately held medical device company, today announced the 6-month follow-up results of the company's European clinical trial evaluating the use of its SAMBA Stent and Delivery System in the treatment of superficial femoral and popliteal artery disease. The SAMBA Stent was designed to treat the highly varied presentation of atherosclerotic disease in the superficial femoral (SFA) and popliteal arteries by providing a unique combination of increased vessel coverage, strength and flexibility.

26 May 2010

Stryker, Acuitec form strategic relationship

Stryker’s Communications business unit and Acuitec announced today that they have signed an agreement that will integrate both companies’ technologies within the operating room to provide customers with a comprehensive offering that combines in-room integration with desirable workflow solutions.

From Stryker 25 May 2010

Arthrosurface achieves significant clinical milestone in implant technology

Arthrosurface, Inc., the developer of inlay joint resurfacing systems, announced the achievement of a significant clinical milestone.

25 May 2010

X-spine's new Fixcet Spinal Facet Screw System receives FDA clearance

X-spine, a global manufacturer of implants and instruments for spinal surgery, announced FDA clearance of its new Fixcet Spinal Facet Screw System. The system is designed to provide spinal stability for lumbar fusion procedures, including the treatment of degenerative disk disease, instability and trauma.

25 May 2010

Research work holds promise for biological substitute for dental implants

A technique pioneered in the Tissue Engineering and Regenerative Medicine Laboratory of Dr. Jeremy Mao, the Edward V. Zegarelli Professor of Dental Medicine at Columbia University Medical Center, can orchestrate stem cells to migrate to a three-dimensional scaffold infused with growth factor, holding the translational potential to yield an anatomically correct tooth in as soon as nine weeks once implanted.

24 May 2010

Patients with VAD implants develop varying severities of AVWS

The findings of a 12 patient study recently published in Thrombosis and Haemostasis by University Medical Center Freiburg documented that patients implanted with a ventricular assist device (VAD) experienced a rapid onset of acquired von Willebrand syndrome (AVWS), while patients implanted with the SynCardia temporary Total Artificial Heart did not.

21 May 2010

Stryker resolves FDA Warning Letters

Stryker Corporation today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that the actions undertaken to address issues raised in two Warning Letters received in 2007 and 2009 are sufficient.

From Stryker 20 May 2010

StemSave lauds research on new technique that can orchestrate body's own stem cells to regenerate teeth

In a statement today, StemSave Inc., the market leader in the field of stem cell recovery and cryo-preservation lauds research published in the current issue of the Journal of Dental Research citing a new technique pioneered by the authors that can orchestrate the body's own stem cells to regenerate teeth. StemSave commends the authors for their groundbreaking work.

19 May 2010

New book on history and future of medical technology

Some health care reform advocates complain that physicians rely too much on expensive technology. Published by Telescope Books, The History and Future of Medical Technology shows that today's medical technologies are worth every penny—saving lives, improving patients' quality of life, and helping doctors diagnose diseases during the earliest, most treatable stages.

19 May 2010

Sonova Group financial year 2009/10 sales increase 20.1% to CHF 1,500.3 million

The Sonova Group increased its sales in financial year 2009/10 to CHF 1,500.3 million from CHF 1,249.2 million, thus posting an excellent growth rate of 20.1% in Swiss francs, despite a negative currency effect of 3.7%. The Group achieved organic growth of 18.4% in local currencies, which significantly surpassed the market as a whole. Market growth in 2009/10 is estimated at around 4% in units sold.

18 May 2010

Hospitals to get more bargaining clout for medical devices

The Wall Street Journal: "Hospitals lack leverage when negotiating prices for high-cost implants like defibrillators and replacement hips because individual doctors, rather than hospitals, typically select the products they use in their patients. Since these doctors often aren't hospital employees, they have little incentive to bargain-hunt.

17 May 2010

Heart defibrillators complicate end-of-life care

Heart defibrillators, "small implants that save lives by sending an electrical jolt to interrupt a potentially fatal heart rhythm and restore normal beating," can pose a "challenge near life's end, for both patients and their families," The New York Times reports.

14 May 2010

First international user meeting of endoscopic spinal surgery

On 14 and 15 May 2010 joimax GmbH holds the first international user meeting of endoscopic spinal surgery in Veenhuizen/Niederlande. Besides the ten reference surgeons about 30 participants and customers from Germany, Europe, the United States and other countries are expected to join the meeting. The scientific program comprises a two-day conference which will be opened with a keynote lecture of Prof. Dr. Gerbrand J. Groen of the university of Utrecht.

14 May 2010

Study results of Cameron Health's S-ICD- System published online in NEJM

Cameron Health, Inc. today announced the publication of study results online in the New England Journal of Medicine highlighting the development and potential benefits of the company's S-ICD- System, the first minimally invasive, subcutaneous implantable cardioverter defibrillator, for the treatment of sudden cardiac arrest.

14 May 2010

New Melody Transcatheter Pulmonary valve helps congenital heart defect patients avoid multiple surgeries

Congenital heart defects are the most common type of major birth defect in the U.S., affecting about 25,000 babies each year. Now, a new valve being used at the University of Michigan's C.S. Mott Children's Hospital Congenital Heart Center can help patients delay or avoid multiple surgeries.

13 May 2010

FDA approves St. Jude Medical's Unify CRT-D and Fortify ICD devices

St. Jude Medical, Inc., a global medical device company, today announced U.S. Food and Drug Administration (FDA) approval and first U.S. implants of its Unify™ cardiac resynchronization therapy defibrillator (CRT-D) and Fortify™ implantable cardioverter defibrillator (ICD). The new devices feature advanced battery technology and circuitry that allow for the smallest device footprint in the industry and rapid charge times, without any compromise in device longevity or power.

13 May 2010

Boston Scientific receives CE Mark approval for TAXUS Element Paclitaxel-Eluting Coronary Stent System

Angiotech Pharmaceuticals, Inc. today announced that its corporate partner, Boston Scientific Corporation, has received CE Mark approval for its TAXUS(R) Element(TM) Paclitaxel-Eluting Coronary Stent System, Boston Scientific's third-generation drug-eluting stent (DES) technology.

13 May 2010

New disposable measuring device monitors body's vital functions

Physiological signals can nowadays be easily monitored with measurement devices implanted inside a living body. The object - animal or human - is barely aware of the presence of the implant.

11 May 2010